Real-World Efficacy and Safety of Avelumab Plus Axitinib in Metastatic Renal Cell Carcinoma: Results from the Ambispective RAVE-Renal Study

Real-World Efficacy and Safety of Avelumab Plus Axitinib in Metastatic Renal Cell Carcinoma: Results from the Ambispective RAVE-Renal Study

Background: The RAVE-Renal study was conducted to evaluate the real-world efficacy and safety of avelumab plus axitinib as a first-line therapy for patients with metastatic renal cell carcinoma (mRCC). Methods: RAVE-Renal was a multicenter, noninterventional, ambispective study with both retrospecti...

Full description

Saved in:
Bibliographic Details
Main Authors: Ilya Tsimafeyeu, Vyacheslav Chubenko, Olga Baklanova, Alexey Kalpinskiy, Sufia Safina, Andrei Lebedinets, Vladislav Petkau, Elvira Parsadanova, Maria Turganova, Aleksei Shkurat, Natalia Tovbik, Elena Tkacheva, Yulia Anzhiganova, Olga Novikova, Varvara Bragina, Ruslan Zukov, Rashida Orlova
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Current Oncology
Subjects:
avelumab plus axitinib
first-line therapy
metastatic renal cell carcinoma
RAVE-Renal ambispective study
Online Access:https://www.mdpi.com/1718-7729/32/1/11
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1718-7729/32/1/11

Similar Items